LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$690.00 |
| 52 Week High | US$740.00 |
| 52 Week Low | US$334.00 |
| Beta | 0.37 |
| 1 Month Change | 2.22% |
| 3 Month Change | 26.61% |
| 1 Year Change | 106.59% |
| 3 Year Change | 345.16% |
| 5 Year Change | 452.00% |
| Change since IPO | 2,310.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| LLY | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -2.1% | -1.5% | -1.8% |
| 1Y | 106.6% | -12.9% | -3.8% |
Return vs Industry: LLY exceeded the Swiss Pharmaceuticals industry which returned -12.4% over the past year.
Return vs Market: LLY exceeded the Swiss Market which returned -3.6% over the past year.
Price Volatility
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 3.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: LLY's share price has been volatile over the past 3 months.
Volatility Over Time: LLY's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LLY fundamental statistics | |
|---|---|
| Market cap | CHF617.08b |
| Earnings (TTM) | CHF4.78b |
| Revenue (TTM) | CHF31.14b |
128.2x
P/E Ratio19.7x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY income statement (TTM) | |
|---|---|
| Revenue | US$34.12b |
| Cost of Revenue | US$7.08b |
| Gross Profit | US$27.04b |
| Other Expenses | US$21.80b |
| Earnings | US$5.24b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 5.82 |
| Gross Margin | 79.25% |
| Net Profit Margin | 15.36% |
| Debt/Equity Ratio | 233.4% |
How did LLY perform over the long term?
See historical performance and comparison